Evidence map›Paper›PMID 38275043›Full record

ReviewCurrent drug delivery2025

Recent Developments in Tyrosine Kinase Inhibitor-based Nanotherapeutics for EGFR-resistant Non-small Cell Lung Cancer.

Eknath Kole, Krishna Jadhav, Raghuraj Singh, Shilpa Mandpe, Ashwin Abhang, Rahul K Verma, Jitendra Naik

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current drug delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Eknath KoleDepartment of Pharmaceutical Technology, University Institute of Chemical Technology, KBC North Maharashtra University, Jalgaon M.S., 425001, India.ORCID 0000-0002-0782-581X
Krishna JadhavPharmaceutical Nanotechnology Lab, Institute of Nano Science and Technology, Sahibzada Ajit Singh Nagar (Mohali), Punjab, 140306, India.ORCID 0000-0002-5875-2315
Raghuraj SinghPharmaceutical Nanotechnology Lab, Institute of Nano Science and Technology, Sahibzada Ajit Singh Nagar (Mohali), Punjab, 140306, India.
Shilpa MandpeDepartment of Pharmaceutical Technology, University Institute of Chemical Technology, KBC North Maharashtra University, Jalgaon M.S., 425001, India.
Ashwin AbhangDepartment of Biopharmaceutics, Biocon Bristol-Myers Squibb R&D Center (BBRC), Bangalore, India.
Rahul K VermaPharmaceutical Nanotechnology Lab, Institute of Nano Science and Technology, Sahibzada Ajit Singh Nagar (Mohali), Punjab, 140306, India.
Jitendra NaikDepartment of Pharmaceutical Technology, University Institute of Chemical Technology, KBC North Maharashtra University, Jalgaon M.S., 425001, India.
Kavayitri Bahinabai Chaudhari North Maharashtra University · INNational Institute of Pharmaceutical Education and Research · INBristol-Myers Squibb (India) · IN

Funding

University Grants Commission (UGC), New Delhi, India F. 19-251/2020 (BSR)
6 · The paper itself

Abstract

The advent of drug resistance in response to epidermal growth factor receptor (EGFR)- tyrosine kinase inhibitor (TKI) targeted therapy represents a serious challenge in the management of non-small cell lung cancer (NSCLC). These acquired resistance mutations, attributed to several advanced EGFR mutations and, necessitated the development of new-generation TKIs. Nanomedicine approaches provide a plausible way to address these problems by providing targeted delivery and sustained release, which have demonstrated success in preclinical trials. This review article provides a summary of nano-formulations designed for EGFR-TKI-resistant NSCLC, highlighting their efficacy in both

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungLung NeoplasmsNanoparticlesProtein Kinase InhibitorsAnimalsDrug Resistance, NeoplasmErbB ReceptorsHumansNanomedicineTyrosine Kinase InhibitorsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsTyrosine Kinase Inhibitorscombination therapyEGFR-TKI resistanceepidermal growth factor receptor (EGFR)nanoparticles.Non-small cell lung cancer (NSCLC)tyrosine kinase inhibitor (TKI)

Identifiers

PMID38275043
OpenAlexW4391219911

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.